The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The FDA grants PTX-200 Orphan Drug Designation for the treatment of AML
On 1st May 2017, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PTX-200 for the treatment of patients with Acute Myeloid Leukemia (AML).1
Akt, a serine/threonine protein kinase, is constitutively phosphorylated and hyper-activated in several diseases including AML. High levels of phosphorylated Akt is associated with adverse outcomes in AML patients.2 PTX-200 (triciribine phosphate monohydrate) is a potent small molecule inhibitor that specifically inhibits Akt by a different mechanism, and so is comparably safer, compared to other non-specific kinase inhibitors.
Currently, PTX-200 is being explored in a phase 1/2 study (NCT02930109), which is aiming to assess the safety and efficacy of PTX-200 in combination with cytarabine in patients with relapsed or refractory AML.
References
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?